Related Experiment Video
Updated: Aug 13, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
Reassessing R&D outcomes of leading pharmaceutical companies
Alexander Schuhmacher1, Michael Witting2, Dominik Hartl3
1Technische Hochschule Ingolstadt, Germany; University of St Gallen, Switzerland.
Abstract:
This analysis investigated 118 new drugs approved by the FDA for leading pharmaceutical companies between 2002 and 2012 and their commercial outcome through 2024. Focusing on R&D effectiveness, we found that 67% generated sufficient revenues to recover estimated standard R&D costs. R&D profitability varied by sourcing strategy, orphan drug designation status and therapeutic area, whereas therapeutic novelty and regulatory innovativeness showed no meaningful difference. Overall, the findings indicate that R&D productivity of large pharmaceutical companies might be more effective than previously assumed. Thus, the insights highlight the importance of strategic choices in shaping R&D productivity, with implications for aligning R&D strategy and R&D models.
Related Concept Videos
Drug Discovery: Overview
Preclinical Development: Overview
Clinical Trials: Overview
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Biopharmaceutical Factors Influencing Drug Product Design: Overview
Drug Regulation